Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference
17 September 2019 - 9:00PM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September
24, 2019 at 12:00 p.m. Eastern Time.
A live webcast of the presentation will be
available under the “For Investors” section of the Antares website,
www.antarespharma.com. A replay of the webcast will also be
archived on Antares’ website for 90 days following the
presentation.
About Antares Pharma
Antares Pharma, Inc. is a combination drug
device company focused primarily on the development and
commercialization of self-administered parenteral pharmaceutical
products using advanced drug delivery auto injector technology. The
Company has a portfolio of proprietary and partnered commercial
products with several product candidates in various stages of
development, as well as significant strategic alliances with
industry leading pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc.
and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary products
include XYOSTED® (testosterone enanthate) injection, OTREXUP®
(methotrexate) injection for subcutaneous use and Sumatriptan
Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: market acceptance, adequate
reimbursement coverage and commercial success of XYOSTED™ and
future revenue from the same; market acceptance of Teva’s generic
epinephrine auto-injector product and future revenue from the same;
future market acceptance and revenue from Makena® subcutaneous auto
injector; Teva’s ability to successfully commercialize VIBEX®
Sumatriptan Injection USP and the amount of revenue from the same;
continued growth of prescriptions and sales of OTREXUP®; the
timing and results of the Company’s or its partners’ research
projects or clinical trials of product candidates in development
including projects with Teva and Pfizer and our proprietary
programs for ATRS-1701 and our development program for the
use of subcutaneous methotrexate for the treatment of ectopic
pregnancy; actions by the FDA or other regulatory agencies with
respect to the Company’s products or product candidates of its
partners; successful completion of the transaction with Ferring
International Center, S.A.; continued growth in product,
development, licensing and royalty revenue; achievement of the
updated 2019 revenue guidance; the Company’s ability to meet loan
extension and interest only payment milestones and the ability to
repay the debt obligation with Hercules Capital; the Company’s
ability to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:
Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Apr 2024 to May 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From May 2023 to May 2024